# Kailera Therapeutics Inc. (KLRA)

Source: https://www.quantisnow.com/company/KLRA
Generated: 2026-11-19T11:43:06.125Z

- Ticker: KLRA
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2026
- SEC CIK: 0002096997

## Latest KLRA news and filings

- 2026-11-10 12:00 UTC [Conference Announcement] [Kailera Therapeutics to Present at ObesityWeek 2026](https://www.quantisnow.com/insight/kailera-therapeutics-to-present-at-obesityweek-2026-6782677)
- 2026-11-09 12:40 UTC [Analyst Coverage Initiated] [Canaccord Genuity initiated coverage on Kailera Therapeutics with a new price target](https://www.quantisnow.com/insight/canaccord-genuity-initiated-coverage-on-kailera-therapeutics-with-a-new-6780261)
- 2026-11-04 21:11 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Kailera Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-kailera-therapeutics-inc-6772652)
- 2026-11-04 21:08 UTC [SEC Form 8-K] [Kailera Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/kailera-therapeutics-inc-filed-sec-form-8-k-results-of-operations-6772559)
- 2026-11-04 21:05 UTC [Earnings] [Kailera Reports Third Quarter 2026 Financial Results and Provides Business Updates](https://www.quantisnow.com/insight/kailera-reports-third-quarter-2026-financial-results-and-provides-business-6772343)
- 2026-11-03 12:15 UTC [Conference Announcement] [Kailera Therapeutics to Participate in November Investor Conferences](https://www.quantisnow.com/insight/kailera-therapeutics-to-participate-in-november-investor-conferences-6768409)
- 2026-10-01 10:45 UTC [Kailera Therapeutics Presents New Clinical Data at EASD 2026 Annual Meeting](https://www.quantisnow.com/insight/kailera-therapeutics-presents-new-clinical-data-at-easd-2026-annual-6731284)
- 2026-09-30 11:00 UTC [Kailera Therapeutics Announces Completion of Enrollment in KaiNETIC Global Phase 3 Clinical Program of GLP-1/GIP Receptor Dual Agonist Ribupatide Injection](https://www.quantisnow.com/insight/kailera-therapeutics-announces-completion-of-enrollment-in-kainetic-global-phase-6729849)
- 2026-09-16 11:00 UTC [Conference Announcement] [Kailera Therapeutics to Participate in September Investor Conferences](https://www.quantisnow.com/insight/kailera-therapeutics-to-participate-in-september-investor-conferences-6716856)
- 2026-09-09 23:29 UTC [SEC Form 4] [SEC Form 4 filed by Chief Technology Officer Nicholson Nur](https://www.quantisnow.com/insight/sec-form-4-filed-by-chief-technology-officer-nicholson-nur-6710553)
- 2026-09-09 23:23 UTC [SEC Form 3] [SEC Form 3 filed by new insider Nicholson Nur](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-nicholson-nur-6710548)
- 2026-08-14 12:03 UTC [SEC Form SCHEDULE 13G filed by Kailera Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-schedule-13g-filed-by-kailera-therapeutics-inc-6681900)
- 2026-08-12 20:29 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Kailera Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-kailera-therapeutics-inc-6678189)
- 2026-08-12 20:20 UTC [SEC Form 8-K] [Kailera Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/kailera-therapeutics-inc-filed-sec-form-8-k-results-of-operations-6678110)
- 2026-08-12 20:05 UTC [Conference Announcement] [Kailera Reports Second Quarter 2026 Financial Results and Provides Business Updates](https://www.quantisnow.com/insight/kailera-reports-second-quarter-2026-financial-results-and-provides-business-6677759)
- 2026-08-11 11:00 UTC [Leadership Update] [Kailera Therapeutics Appoints Nur Nicholson as Chief Technology Officer](https://www.quantisnow.com/insight/kailera-therapeutics-appoints-nur-nicholson-as-chief-technology-officer-6674833)
- 2026-08-05 10:04 UTC [SEC Form SCHEDULE 13G filed by Kailera Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-schedule-13g-filed-by-kailera-therapeutics-inc-6663634)
- 2026-07-08 20:20 UTC [SEC Form 4] [SEC Form 4 filed by Officer Tregoning Kathleen](https://www.quantisnow.com/insight/sec-form-4-filed-by-officer-tregoning-kathleen-6631649)
- 2026-07-08 20:15 UTC [SEC Form 3] [SEC Form 3 filed by new insider Tregoning Kathleen](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-tregoning-kathleen-6631615)
- 2026-07-07 11:00 UTC [Kailera Therapeutics Announces Positive Topline Data from Two Hengrui Pharma Phase 3 Clinical Trials of Oral Small Molecule GLP-1 Receptor Agonist HRS-7535/KAI-7535](https://www.quantisnow.com/insight/kailera-therapeutics-announces-positive-topline-data-from-two-hengrui-pharma-6629346)
- 2026-06-29 11:30 UTC [Leadership Update] [Kailera Therapeutics Appoints Kathleen Tregoning as Chief Corporate Affairs Officer](https://www.quantisnow.com/insight/kailera-therapeutics-appoints-kathleen-tregoning-as-chief-corporate-affairs-officer-6618241)
- 2026-06-11 20:05 UTC [SEC Form 4] [CEO & President Renaud Ronald C Jr exercised 38,094 shares at a strike of $5.25 (SEC Form 4)](https://www.quantisnow.com/insight/ceo-president-renaud-ronald-c-jr-exercised-38094-shares-at-6598851)
- 2026-06-05 23:32 UTC [Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026](https://www.quantisnow.com/insight/hengrui-pharma-and-kailera-therapeutics-present-ribupatide-clinical-data-at-6592188)
- 2026-05-28 20:05 UTC [Conference Announcement] [Kailera Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference](https://www.quantisnow.com/insight/kailera-therapeutics-to-present-at-the-2026-jefferies-global-healthcare-6576973)
- 2026-05-26 20:29 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Kailera Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-kailera-therapeutics-inc-6572525)
- 2026-05-26 20:18 UTC [SEC Form 8-K] [Kailera Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/kailera-therapeutics-inc-filed-sec-form-8-k-results-of-operations-6572377)
- 2026-05-26 20:02 UTC [Public Offering] [Kailera Reports First Quarter 2026 Financial Results and Provides Clinical Data Updates](https://www.quantisnow.com/insight/kailera-reports-first-quarter-2026-financial-results-and-provides-clinical-6571986)
- 2026-05-13 11:30 UTC [Hengrui Pharma and Kailera Therapeutics Announce Clinical Data Presentations at the American Diabetes Association 86th Scientific Sessions](https://www.quantisnow.com/insight/hengrui-pharma-and-kailera-therapeutics-announce-clinical-data-presentations-at-6549659)
- 2026-05-12 12:32 UTC [Analyst Coverage Initiated] [Analyst initiated coverage on Kailera Therapeutics with a new price target](https://www.quantisnow.com/insight/analyst-initiated-coverage-on-kailera-therapeutics-with-a-new-price-6546934)
- 2026-05-12 12:32 UTC [Analyst Coverage Initiated] [William Blair initiated coverage on Kailera Therapeutics](https://www.quantisnow.com/insight/william-blair-initiated-coverage-on-kailera-therapeutics-6546933)
- 2026-05-12 12:32 UTC [Analyst Coverage Initiated] [Leerink Partners initiated coverage on Kailera Therapeutics with a new price target](https://www.quantisnow.com/insight/leerink-partners-initiated-coverage-on-kailera-therapeutics-with-a-new-6546932)
- 2026-05-12 12:32 UTC [Analyst Coverage Initiated] [TD Cowen initiated coverage on Kailera Therapeutics with a new price target](https://www.quantisnow.com/insight/td-cowen-initiated-coverage-on-kailera-therapeutics-with-a-new-6546931)
- 2026-05-12 12:32 UTC [Analyst Coverage Initiated] [Evercore ISI initiated coverage on Kailera Therapeutics](https://www.quantisnow.com/insight/evercore-isi-initiated-coverage-on-kailera-therapeutics-6546930)
- 2026-05-12 12:32 UTC [Analyst Coverage Initiated] [Jefferies initiated coverage on Kailera Therapeutics with a new price target](https://www.quantisnow.com/insight/jefferies-initiated-coverage-on-kailera-therapeutics-with-a-new-price-6546929)
- 2026-04-24 00:01 UTC [SEC Form SCHEDULE 13D filed by Kailera Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-schedule-13d-filed-by-kailera-therapeutics-inc-6513318)
- 2026-04-23 23:34 UTC [SEC Form SCHEDULE 13D filed by Kailera Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-schedule-13d-filed-by-kailera-therapeutics-inc-6513303)
- 2026-04-22 20:15 UTC [SEC Form 4] [SEC Form 4 filed by Rtw Investments, Lp](https://www.quantisnow.com/insight/sec-form-4-filed-by-rtw-investments-lp-6510481)
- 2026-04-22 10:03 UTC [SEC Form 4] [SEC Form 4 filed by Jiangsu Hengrui Pharmaceuticals Co., Ltd.](https://www.quantisnow.com/insight/sec-form-4-filed-by-jiangsu-hengrui-pharmaceuticals-co-ltd-6509228)
- 2026-04-22 09:40 UTC [Hengrui Pharma Reports Q1 2026 Results with Revenue and Net Profit Growth](https://www.quantisnow.com/insight/hengrui-pharma-reports-q1-2026-results-with-revenue-and-net-6509158)
- 2026-04-20 22:10 UTC [SEC Form 4] [SEC Form 4 filed by Bain Capital Investors Llc](https://www.quantisnow.com/insight/sec-form-4-filed-by-bain-capital-investors-llc-6507194)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/KLRA
- Earnings history: https://www.quantisnow.com/earnings/KLRA
- Dividend history: https://www.quantisnow.com/dividends/KLRA
- Insider transactions: https://www.quantisnow.com/insiders/KLRA
- Options chain: https://www.quantisnow.com/options/KLRA
- SEC 8-K filings only: https://www.quantisnow.com/company/KLRA/8-k
- RSS and alerts for KLRA: https://www.quantisnow.com/docs/rss-feeds.md
